Physician profile
Jan M Lopes
NPI 1104320175
$24,657.67
in general payments reported to CMS, 2019-2025
18 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.94 · 2022: $183 · 2023: $159 · 2024: $3,183 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $15K · Food and Beverage: $9,398 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $14,878.57 |
| Food and Beverage | $9,397.68 |
| Education | $148.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12,727.13 | 2024-2025 | Farapulse, General - Therapies, Ingevity+ |
| Medtronic, INC. | $5,037.29 | 2024-2025 | Micra, Amplia Mri Quad Crt-D Surescan, Affera Mapping System |
| Abbott Laboratories | $2,914.92 | 2025 | Ensite, Advisor, Aveir |
| Biotronik INC. | $2,733.72 | 2024-2025 | Selectra, Biomonitor, Rivacor 7 Dr-T |
| Biosense Webster, INC. | $262.17 | 2024-2025 | Carto 3, Qdot Micro, Nuvision Ice Catheter |
| Atricure, INC. | $244.12 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Abiomed | $147.37 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $84.17 | 2021-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $75.82 | 2022-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $75.60 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $74.86 | 2023-2024 | |
| Vital Connect, INC | $71.62 | 2025 | Vitalpatch Rtm |
| Pfizer INC. | $67.88 | 2022-2024 | |
| Heartflow, INC. | $39.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $36.71 | 2021-2024 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $23.74 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Cvrx, INC. | $23.41 | 2023 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $17.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Lopes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.